Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of Anti-CD19 CAR T-Cell Immunotherapy for B-cell Leukemias
NCT06364423Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of mivocabtagene autoleucel in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Sep 2024; status: recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06364423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364423.